Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- End Stage Renal Disease
- Type
- Interventional
- Phase
- Phase 2Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Treatment: Envarsus® 0.07-0.14 mg/kg/day every morning Control: Generic tacrolimus 0.1-0.2 mg/kg/day in 2 divided doses given every 12 hours Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
Participants will be identified through the Department of Transplantation Surgery at the University of Kentucky. Participants will be pre-screened by the department for entry into the study. The investigator will determine if the participant meets study eligibility requirements. The purpose of this ...
Participants will be identified through the Department of Transplantation Surgery at the University of Kentucky. Participants will be pre-screened by the department for entry into the study. The investigator will determine if the participant meets study eligibility requirements. The purpose of this research is to gather information on how safe and effective of Envarsus® is when compared to twice-daily tacrolimus. The results of this study will be shared with the company providing financial support for the study, the Food and Drug Administration and other federal agencies, if required. All participants that successfully meeting inclusion criteria will be randomized (like the flipping of coin) to Envarsus vs. Tacrolimus at the time of transplant. Participants will be randomized to one of two treatment arms. Treatment begins on post-op day 1. Treatment: Envarsus® 0.07-0.14 mg/kg/day every morning Control: Generic tacrolimus 0.1-0.2 mg/kg/day in 2 divided doses given every 12 hours The total amount of time a person will be asked to volunteer for this study is 9-18 hours over the next 6 months. Participants will need to complete 9 study visits each of these visits will take approximately 1-2 hours to complete. Participants will be given medication dosing diaries to complete throughout the study and will undergo 2 kidney biopsies. Participants will be screened for HIV, Hepatitis B and Hepatitis C viruses.
Tracking Information
- NCT #
- NCT03321656
- Collaborators
- Veloxis Pharmaceuticals
- Investigators
- Principal Investigator: Roberto Gedaly, MD University of Kentucky